C20orf59 Inhibitors
Chemical inhibitors of C20orf59 can exert their inhibitory effects through various mechanisms, each associated with the interruption of specific signaling pathways or enzymatic activities within the cell. Staurosporine acts as a broad-spectrum kinase inhibitor, targeting a wide range of protein kinases. This inhibition can prevent phosphorylation, a post-translational modification essential for the activation of many proteins, including C20orf59, thereby hindering its function. Rapamycin, targeting the mTOR pathway, can modulate the activity of C20orf59 if its function is linked to cell growth or proliferation processes governed by mTOR signaling. LY294002 and Wortmannin both serve as PI3K inhibitors, which can downregulate the PI3K/Akt pathway, a key signaling cascade that, when inhibited, can reduce the activity of proteins such as C20orf59 that may be regulated by this pathway.
Additional inhibitors include U0126 and Trametinib, both targeting MEK1/2 within the ERK pathway. By inhibiting this pathway, they can suppress the activation of proteins that are part of the ERK signaling cascade, which includes C20orf59 if it is indeed a component of this pathway. SB203580, a specific inhibitor of p38 MAPK, can also modulate the function of C20orf59 by targeting this stress-activated protein kinase pathway. Dasatinib, which focuses on Src family kinases, can impede signaling pathways that involve Src kinase activity; if C20orf59 relies on such pathways, its activity would be reduced by Dasatinib. Sorafenib, a multi-kinase inhibitor, can affect C20orf59 by inhibiting RAF kinases and VEGFR, which are part of the angiogenesis and cell signaling processes. Sunitinib, similar to Sorafenib, can suppress receptor tyrosine kinases such as VEGFR and PDGFR, potentially reducing C20orf59 activity if it is associated with pathways involving these kinases. Lastly, SP600125 and ZM-447439 target the JNK signaling pathway and Aurora kinases, respectively. Inhibition of these kinases by SP600125 can decrease C20orf59 activity if it is related to JNK signaling, while ZM-447439 can affect C20orf59 involvement in cell cycle regulation mediated by Aurora kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. C20orf59, as a protein, may be functionally inhibited by staurosporine due to its ability to inhibit the phosphorylation process which is critical for the activation and function of many proteins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR (mammalian target of rapamycin), which is a central regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin can indirectly inhibit C20orf59 if the protein's function is associated with pathways regulated by mTOR activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K/Akt signaling is fundamental to many cellular processes, inhibiting PI3K could downregulate downstream signaling pathways that require C20orf59 function, thereby inhibiting the protein's activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. If C20orf59 is part of the ERK signaling pathway, inhibiting MEK could suppress the ERK pathway's activation and consequently inhibit C20orf59 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAPK. If C20orf59 operates within the p38 MAPK pathway, its inhibition could lead to a functional inhibition of C20orf59. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002. It can functionally inhibit C20orf59 by reducing PI3K/Akt signaling, assuming C20orf59 is associated with this pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If C20orf59 is involved in signaling pathways that rely on Src kinase activity, then Dasatinib could inhibit those pathways and thereby inhibit the functional activity of C20orf59. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF and VEGFR kinases. If C20orf59 is involved in the RAF/MEK/ERK signaling cascade or pathways involving VEGFR, then Sorafenib could inhibit those pathways and indirectly inhibit C20orf59. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, such as VEGFR and PDGFR. If C20orf59's function is tied to signaling pathways involving these kinases, Sunitinib's inhibition of these kinases could lead to the functional inhibition of C20orf59. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase). If C20orf59 is part of the JNK signaling pathway, then by inhibiting JNK, SP600125 could inhibit the functional activity of C20orf59. | ||||||